Synergistic up-regulation of prostaglandin E synthase expression in breast cancer cells by 17beta-estradiol and proinflammatory cytokines.

Inflammatory mediators, such as cytokines and prostaglandins, play a fundamental role in estrogen-dependent breast cancer through their ability to up-regulate aromatase expression and subsequent local production of estrogens in the breast. To study the link between estrogens and inflammation further, we examined the regulation of prostaglandin E synthase (PTGES), a key enzyme in the production of prostaglandin E2. We found that 17beta-estradiol (E2) rapidly and robustly up-regulates PTGES mRNA and protein levels in estrogen receptor (ER)-positive breast cancer cells through ER recruitment to an essential estrogen response element located in the 5' flanking region of the PTGES gene. PTGES is also up-regulated by the proinflammatory cytokines TNFalpha or IL-1beta. Surprisingly, the combination of E2 and cytokines leads to a synergistic up-regulation of PTGES in an ER and nuclear factor-kappaB (NFkappaB)-dependent manner. This is in contrast to the mutual transrepression between ER and NFkappaB that has been well characterized in other cell types. Furthermore, we found enhanced recruitment of ERalpha as well as the NFkappaB family member, p65, to the PTGES estrogen response element by the combination of E2 and TNFalpha compared with either E2 or TNFalpha alone. The synergistic up-regulation of PTGES may result in enhanced prostaglandin E2 production, which in turn may further enhance aromatase expression and production of local estrogens. Our findings suggest that a finely tuned positive feedback mechanism between estrogens and inflammatory factors may exist in the breast and contribute to hormone-dependent breast cancer growth and progression.

[1]  J. Nowak,et al.  CBP Is a dosage-dependent regulator of nuclear factor-kappaB suppression by the estrogen receptor. , 2008, Molecular endocrinology.

[2]  Claire V. Harper,et al.  Human prolactin gene promoter regulation by estrogen: convergence with tumor necrosis factor-alpha signaling. , 2008, Endocrinology.

[3]  R. Tapping,et al.  Microbial Products Stimulate Human Toll-like Receptor 2 Expression through Histone Modification Surrounding a Proximal NF-κB-binding Site* , 2007, Journal of Biological Chemistry.

[4]  Barry Komm,et al.  Estrogen-regulated gene networks in human breast cancer cells: involvement of E2F1 in the regulation of cell proliferation. , 2007, Molecular endocrinology.

[5]  Clifford A. Meyer,et al.  Genome-wide analysis of estrogen receptor binding sites , 2006, Nature Genetics.

[6]  Guillaume Bourque,et al.  Multiplatform genome-wide identification and modeling of functional human estrogen receptor binding sites , 2006, Genome Biology.

[7]  Chin-Yo Lin,et al.  Gene expression preferentially regulated by tamoxifen in breast cancer cells and correlations with clinical outcome. , 2006, Cancer research.

[8]  Shailesh Singh,et al.  Inhibition of cyclooxygenase-2 decreases breast cancer cell motility, invasion and matrix metalloproteinase expression , 2006, BMC Cancer.

[9]  J. Fish,et al.  c-Jun N-terminal Kinase-mediated Stabilization of Microsomal Prostaglandin E2 Synthase-1 mRNA Regulates Delayed Microsomal Prostaglandin E2 Synthase-1 Expression and Prostaglandin E2 Biosynthesis by Cardiomyocytes* , 2006, Journal of Biological Chemistry.

[10]  S. Abramson,et al.  Prostaglandin E2 synthesis and secretion: the role of PGE2 synthases. , 2006, Clinical immunology.

[11]  J. Christman,et al.  Targeted Immunomodulation of the NF-κB Pathway in Airway Epithelium Impacts Host Defense against Pseudomonas aeruginosa1 , 2006, The Journal of Immunology.

[12]  Xinrong Ma,et al.  Prostaglandin E receptor EP4 antagonism inhibits breast cancer metastasis. , 2006, Cancer research.

[13]  M. Costas,et al.  TNF-α enhances estrogen-induced cell proliferation of estrogen-dependent breast tumor cells through a complex containing nuclear factor-kappa B , 2006, Oncogene.

[14]  S. Peters,et al.  Regulatory features of interleukin-1beta-mediated prostaglandin E2 synthesis in airway smooth muscle. , 2006, American journal of physiology. Lung cellular and molecular physiology.

[15]  D. Tatomer,et al.  Distinct roles of unliganded and liganded estrogen receptors in transcriptional repression. , 2006, Molecular cell.

[16]  Sunil Badve,et al.  Microsomal prostaglandin E2 synthase‐1 in breast cancer: a potential target for therapy , 2006, The Journal of pathology.

[17]  Xin Lin,et al.  Overexpression of PKCalpha is required to impart estradiol inhibition and tamoxifen-resistance in a T47D human breast cancer tumor model. , 2005, Carcinogenesis.

[18]  W. Symmans,et al.  Cyclooxygenase-2 protein reduces tamoxifen and N-(4-hydroxyphenyl)retinamide inhibitory effects in breast cancer cells , 2005, Laboratory Investigation.

[19]  T. Hla,et al.  The prostaglandin E2 receptor EP2 is required for cyclooxygenase 2-mediated mammary hyperplasia. , 2005, Cancer research.

[20]  Leslie J Crofford,et al.  Microsomal prostaglandin E synthase-1: the inducible synthase for prostaglandin E2 , 2005, Arthritis research & therapy.

[21]  R. Gaynor,et al.  Formation of an IKKalpha-dependent transcription complex is required for estrogen receptor-mediated gene activation. , 2005, Molecular cell.

[22]  D. Kalaitzidis,et al.  Transcription factor cross-talk: the estrogen receptor and NF-κB , 2005, Trends in Endocrinology & Metabolism.

[23]  Lucia Altucci,et al.  A genomic view of estrogen actions in human breast cancer cells by expression profiling of the hormone-responsive transcriptome. , 2004, Journal of molecular endocrinology.

[24]  J. Frasor,et al.  Selective Estrogen Receptor Modulators , 2004, Cancer Research.

[25]  R. Fulthorpe,et al.  Identification of estrogen-responsive genes by complementary deoxyribonucleic acid microarray and characterization of a novel early estrogen-induced gene: EEIG1. , 2004, Molecular endocrinology.

[26]  R. DuBois,et al.  Cyclooxygenase-2: a potential target in breast cancer. , 2004, Seminars in oncology.

[27]  T. Hla,et al.  Role of prostaglandin E2-dependent angiogenic switch in cyclooxygenase 2-induced breast cancer progression. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[28]  Heike Brand,et al.  Estrogen Receptor-α Directs Ordered, Cyclical, and Combinatorial Recruitment of Cofactors on a Natural Target Promoter , 2003, Cell.

[29]  Barry Komm,et al.  Profiling of estrogen up- and down-regulated gene expression in human breast cancer cells: insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype. , 2003, Endocrinology.

[30]  Guoxiong Xu,et al.  Role of prostaglandin E2 receptors in migration of murine and human breast cancer cells. , 2003, Experimental cell research.

[31]  Philip M. Long,et al.  Breast cancer classification and prognosis based on gene expression profiles from a population-based study , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[32]  P. Barnes,et al.  IL‐1β‐dependent activation of NF‐κB mediates PGE2 release via the expression of cyclooxygenase‐2 and microsomal prostaglandin E synthase , 2003 .

[33]  R. Brueggemeier,et al.  Prostaglandin E2 regulates aromatase activity and expression in human adipose stromal cells via two distinct receptor subtypes. , 2003, The Journal of clinical endocrinology and metabolism.

[34]  T. Yamori,et al.  Development of cDNA microarray for expression profiling of estrogen-responsive genes. , 2002, Journal of molecular endocrinology.

[35]  M. Murakami,et al.  Transcriptional Regulation of the Membrane-associated Prostaglandin E2 Synthase Gene , 2002, The Journal of Biological Chemistry.

[36]  E. Kasarskis,et al.  Tamoxifen enhancement of TNF-α induced MnSOD expression: modulation of NF-κB dimerization , 2002, Oncogene.

[37]  Myles Brown,et al.  Molecular Determinants for the Tissue Specificity of SERMs , 2002, Science.

[38]  R. Brueggemeier,et al.  Molecular pharmacology of aromatase and its regulation by endogenous and exogenous agents , 2001, The Journal of Steroid Biochemistry and Molecular Biology.

[39]  B. Katzenellenbogen,et al.  Synergistic Activation of the Serotonin-1A Receptor by Nuclear Factor-κB and Estrogen , 2001 .

[40]  B. van der Burg,et al.  4-Hydroxytamoxifen Trans-Represses Nuclear Factor-κB Activity in Human Osteoblastic U2-OS Cells through Estrogen Receptor (ER)α, and Not through ERβ. , 2001, Endocrinology.

[41]  M. Jiang,et al.  17 beta-estradiol inhibits tumor necrosis factor-alpha-induced nuclear factor-kappa B activation by increasing nuclear factor-kappa B p105 level in MCF-7 breast cancer cells. , 2000, Biochemical and biophysical research communications.

[42]  C. Lyttle,et al.  The Role of CBP in Estrogen Receptor Cross-Talk with Nuclear Factor-κB in HepG2 Cells. , 2000, Endocrinology.

[43]  A. Purohit,et al.  The regulation of aromatase activity in breast fibroblasts: the role of interleukin-6 and prostaglandin E2. , 1999, Endocrine-related cancer.

[44]  A. Fattorossi,et al.  Tamoxifen induces oxidative stress and apoptosis in oestrogen receptor-negative human cancer cell lines , 1999, British Journal of Cancer.

[45]  B. Katzenellenbogen,et al.  The quinone reductase gene: a unique estrogen receptor-regulated gene that is activated by antiestrogens. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[46]  S. Akira,et al.  Characterization of mechanisms of interleukin-6 gene repression by estrogen receptor , 1997, The Journal of Steroid Biochemistry and Molecular Biology.

[47]  C. Mendelson,et al.  Estrogen biosynthesis proximal to a breast tumor is stimulated by PGE2 via cyclic AMP, leading to activation of promoter II of the CYP19 (aromatase) gene. , 1996, Endocrinology.

[48]  C. Mendelson,et al.  Tumor necrosis factor-alpha stimulates aromatase gene expression in human adipose stromal cells through use of an activating protein-1 binding site upstream of promoter 1.4. , 1996, Molecular endocrinology.

[49]  B. Katzenellenbogen,et al.  Analysis of Mechanisms That Determine Dominant Negative Estrogen Receptor Effectiveness (*) , 1995, The Journal of Biological Chemistry.

[50]  S. Gerstberger,et al.  Control of I kappa B-alpha proteolysis by site-specific, signal-induced phosphorylation , 1995, Science.

[51]  M. Reed,et al.  The interaction of cytokines in regulating oestradiol 17β-hydroxysteroid dehydrogenase activity in MCF-7 cells , 1994, The Journal of Steroid Biochemistry and Molecular Biology.

[52]  D. Kniss,et al.  Nuclear Factor-Kappa B Regulates Inducible Prostaglandin E Synthase Expression in Human Amnion Mesenchymal Cells1 , 2008, Biology of reproduction.

[53]  M. Mendez,et al.  Regulation of the membrane-localized prostaglandin E synthases mPGES-1 and mPGES-2 in cardiac myocytes and fibroblasts. , 2005, American journal of physiology. Heart and circulatory physiology.